The authors suggest this type of labeling may be used in the future to assess oncolytic adenovirus function in animals.
Contact: David T. Curiel, 205-934-8627, david.curiel@ccc.uab.edu, Masato Yamamoto, 205-975-0172, masato.yamamoto@ccc.uab.edu
Large Population-based Study Examines Risk for AML Following Hodgkin Lymphoma
Many people with Hodgkin lymphoma survive their disease; however, these patients are at an increased risk for acute myeloid leukemia (AML) in the years following treatment. Lois B. Travis, M.D., Sc.D., of the National Cancer Institute, and colleagues identified 35,511 1-year Hodgkin lymphoma survivors in Nordic countries and North America between 1970 and 2001 and calculated the excess absolute risk of developing AML. They examined the effect of age at Hodgkin lymphoma diagnosis, whether risk declines after a certain time period, and if there is a lesser risk for patients treated in later calendar years when newer chemotherapy regimens were introduced.
The authors found that the excess absolute risk of AML was highest during the first 10 years after diagnosis with Hodgkin lymphoma, although risk remained elevated after that time period. They observed a greater excess of AML in patients treated at age 35 or older compared with those treated at younger ages. The excess for AML declined substantially after 1984. The authors suggest that modifications in chemotherapy treatment may account for the decreased risk found.
Contact: NCI Pres
'"/>
Contact: Ariel Whitworth
jncimedia@oxfordjournals.org
301-841-1287
Journal of the National Cancer Institute
31-Jan-2006